eXoZymes (NASDAQ:EXOZ) Shares Down 0.4% - Should You Sell?

Key Points

• Analyst sentiment: Weiss Ratings reaffirmed a "Sell (D-)" rating and MarketBeat shows a consensus rating of "Sell."
• Stock action: Shares traded down 0.4% to $10.455 with only 709 shares changing hands (about 90% below average volume); the 50-day MA is $8.83 versus the 200-day MA of $11.37.
• Fundamentals: Market cap is about $88.7M, the company reported a ($0.31) EPS last quarter (P/E -9.68), and it develops enzymes and reagents for molecular biology and diagnostics.

Shares of eXoZymes Inc. (NASDAQ:EXOZ - Get Free Report) traded down 0.4% during trading on Thursday . The stock traded as low as $10.31 and last traded at $10.4550. 709 shares traded hands during trading, a decline of 90% from the average session volume of 7,382 shares. The stock had previously closed at $10.50.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of eXoZymes in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of "Sell".

eXoZymes Trading Down 0.4%

The stock has a market cap of $88.66 million, a price-to-earnings ratio of -9.68 and a beta of 2.53. The firm's 50 day moving average is $8.83 and its two-hundred day moving average is $11.37. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 0.02.

eXoZymes (NASDAQ:EXOZ - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.31) earnings per share for the quarter.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company's enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.